Dr. Reddy’s Laboratories

Name

Dr. Reddy’s Laboratories

Legal name

Dr. Reddy's Laboratories, Ltd.

Website

https://drreddys.com

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Generic pharmaceuticals
• Active pharmaceutical ingredients
• Biosimilar development
• Pharmaceutical contract manufacturing
• Innovative drug development

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Generics (Branded, Unbranded, Biosimilars): Core business segment delivering advanced medicines at affordable prices across major therapeutic areas including oncology, gastroenterology, and dermatology. Revenue declined due to loss of Revlimid exclusivity but remains the largest revenue driver.
2. API & Services: Development and manufacturing of high-quality APIs for pharmaceutical companies globally. Offers end-to-end pharmaceutical services including CDMO through Aurigene subsidiary. Supplies APIs to 80+ countries with 250+ products.
3. Innovative Medicines: Advancing therapies that address unmet medical needs through science and technology, including Toripalimab (immuno-oncology), Lenacapavir (HIV), and CAR-T cell therapy through Aurigene Oncology.
4. Consumer Health: Broad portfolio including OTC products and health solutions supporting everyday well-being.
5. XACDURO Distribution Agreement: Exclusive distribution and licensing agreement with Innoviva Specialty Therapeutics for antibiotic XACDURO covering South and Central America, Caribbean, Russia, and CIS countries.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Dr. Reddy's Laboratories is an integrated pharmaceutical company that develops, manufactures, and commercializes affordable generic medicines, biosimilars, Active Pharmaceutical Ingredients (APIs), innovative therapies, and consumer health products. It supplies 250+ APIs to 80+ countries and operates 8 USFDA-inspected manufacturing sites, with notable launches including Bosutinib Tablets 400mg in the US, Obeda oral semaglutide in India, and generic semaglutide injection in Canada.

Product overview

Dr. Reddy's Laboratories operates as a diversified pharmaceutical company organized across four main segments: Generics (branded, unbranded, and biosimilars), API & Services (development, manufacturing, and research support), Innovative Medicines, and Consumer Health solutions. The company also operates through subsidiaries including Aurigene Pharmaceutical Services (CRDMO services) and Aurigene Oncology (cancer treatments). Key products include biosimilar oncology treatments (Bevacizumab, Rituximab), innovative immunotherapies (Toripalimab), HIV treatments (Lenacapavir), and diabetes therapies (Obeda semaglutide). The company offers over 250 active pharmaceutical ingredients through its API Solutions business and serves markets in 80+ countries. Recent launches include Bosutinib Tablets 400mg (generic leukemia treatment) and Obeda oral semaglutide (diabetes). The company also provides digital patient support programs through platforms like Alivius (cancer patient tracking), Mintop Daily (hair loss support), and Vega Club (IBD management).

Differentiator

Problem solved

Functional benefit

Brands

• Obeda: Oral semaglutide biosimilar brand for Type 2 diabetes
• Aurigene
• Aurigene.AI
• XCEED
• Dr. Reddy's Direct
• Dr. Reddy's API

Products and services

• Generic Medicines Portfolio Branded, unbranded, and biosimilar generic medicines delivered across major therapeutic areas including oncology, gastroenterology, and dermatology, sold to distributors, healthcare providers, and patients across 80+ countries.
• Active Pharmaceutical Ingredients (APIs) Manufacturing and supply of 250+ high-quality, affordable Active Pharmaceutical Ingredients supplied to generic formulations manufacturers across 80+ countries, produced at 8 USFDA-inspected manufacturing sites.
• Innovative Medicines Novel therapies addressing unmet medical needs including immuno-oncology, HIV, and rare disease treatments, developed through internal R&D and partnerships with innovators like Gilead Sciences and Alvotech.
• Consumer Health Products Broad portfolio of OTC products and health solutions supporting everyday well-being including dermatology and trichology offerings such as Mintop Daily for hair loss support.
• Toripalimab The first immunotherapy approved by major global regulators for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC); introduces immuno-oncology as a first-line treatment for RM-NPC in combination with chemotherapy in India.
• Bevacizumab Biosimilar First biosimilar of Bevacizumab approved and launched in the UK; treatment for colorectal, lung, brain, kidney, cervical, and ovarian cancers that works by blocking VEGF protein to slow cancer growth and spread.
• Lenacapavir Long-acting, USFDA-approved treatment for HIV-1 infection; Dr. Reddy's partnership with Gilead Sciences aims to manufacture and commercialize across 120 countries.
• Obeda (Oral Semaglutide) Oral semaglutide biosimilar for Type 2 diabetes management launched in India, available in 3mg (Rs 99), 7mg (Rs 135), and 14mg (Rs 225) tablet strengths; approved by CDSCO following Phase III clinical study on 288 patients demonstrating non-inferior efficacy.
• Bosutinib Tablets 400mg First generic version of Pfizer's Bosulif for treatment of Philadelphia chromosome-positive chronic myeloid leukemia; first-to-market launch with 180-day generic exclusivity in the US market, developed in collaboration with MSN Laboratories.
• Generic Semaglutide Injection Generic semaglutide injection for Type 2 diabetes supplied as a sterile solution in pre-filled pens available in 2mg/pen and 4mg/pen strengths; Canada became the first G7 country to grant market authorization following Health Canada's Notice of Compliance on April 28, 2026.
• CAR T-Cell Therapy Novel therapeutic solution for patients with relapsed/refractory Multiple Myeloma (RRMM), a cancer of plasma cells; developed by Aurigene Oncology subsidiary with Phase 1 study results announced.
• Aurigene Pharmaceutical Services (CRDMO) Contract Research, Development and Manufacturing Organization offering integrated services across drug discovery, APIs, and finished dosage forms for small and large molecules from lab to market, powered by the Aurigene.AI drug discovery platform.

Quantifiable outcome

• Over 1.5 billion patient lives targeted by 2030
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core, minor and flagship.

• Innoviva Specialty TherapeuticscoreChannel Partner/ Reseller/ Distributor · 16 June 2026Exclusive distribution and licensing agreement for XACDURO, an FDA-approved antibiotic for hospital-acquired and ventilator-associated bacterial pneumonia, covering South and Central America, Caribbean, Russia, and CIS countries. Dr. Reddy's handles development, regulatory approval, and commercialization.
• AlvotechcoreStrategic or Co-development Partner · 5 June 2025Collaboration to expand access to essential cancer therapies approved for more than 40 types of cancer, strengthening oncology care and supporting patients with high-burden diseases worldwide. Partnership involves biosimilar development including pembrolizumab.
• Nimbus Health GmbHminorStrategic or Co-development Partner · 4 February 2022Acquisition agreement for German medical cannabis firm Nimbus Health GmbH, a pioneer in Germany's medical cannabis sector valued at approximately €122 million.
• Gates FoundationflagshipStrategic or Co-development PartnerWorking to develop an injectable contraceptive for low and middle income countries, advancing women's health, improving family planning options, and reducing health inequities.
• SanoficoreChannel Partner/ Reseller/ DistributorPartnering to distribute pediatric and adult vaccines in India, expanding immunization coverage, and strengthening disease prevention.
• MSN LaboratoriescoreStrategic or Co-development PartnerCollaboration for Bosutinib Tablets 400mg development and manufacturing. MSN handled development and manufacturing while Dr. Reddy's holds exclusive US marketing rights, securing 180-day first-to-file generic exclusivity.
• Aurigene Pharmaceutical ServicescoreStrategic or Co-development PartnerWholly-owned subsidiary of Dr. Reddy's formed in 2020 by consolidating service businesses. Offers integrated CRO and CDMO services for small and large molecules from lab to market, with AI-powered drug discovery platform.
• Aurigene OncologycoreStrategic or Co-development PartnerSubsidiary developing innovative treatments to improve lives of people with cancer and inflammatory diseases, including CAR-T cell therapy for relapsed/refractory Multiple Myeloma.
• Industrial Promotion Services (IPS)minorStrategic or Co-development PartnerStrategic collaboration to support the East African Combined Pharmaceutical Center (EACPC) in Kenya, supporting pharmaceutical manufacturing localization in Africa.
• Mankind PharmaminorOthersJoint discussion on podcast WTF with Nikhil Kamath regarding India's pharmaceutical industry evolution and growth from generics to innovation-led growth.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cipla: Indian pharma major with overlapping generics, API, and respiratory/oncology portfolios and similar emerging-market distribution depth. A close competitor across Africa, India, and the US generics market.
• Biocon: Indian biopharmaceutical peer with leading biosimilars (Trastuzumab, Bevacizumab, Insulin Glargine) and a CDMO arm (Syngene). Highly comparable to Dr. Reddy's on biosimilars strategy and Aurigene-style CRDMO ambitions.
• Sun Pharmaceutical Industries: Largest Indian pharmaceutical company with comparable generics, API, and specialty franchises serving the US, India, and emerging markets. Directly competes in generic oncology, dermatology, and complex generics where Dr. Reddy's is also active.
• Aurobindo Pharma: Direct competitor in US generics, APIs, and biosimilars with comparable manufacturing scale and USFDA-inspected facilities. Closely comparable on injectable generics and emerging-market expansion strategies.
• Zydus Lifesciences: Indian integrated pharma with generics, APIs, biologics, and consumer health businesses. Overlaps heavily with Dr. Reddy's biosimilar pipeline (including their own Bevacizumab) and US generics franchise.
• Glenmark Pharmaceuticals: Indian peer with parallel generics, API, and specialty branded businesses and a growing complex generics and biosimilars pipeline. Comparable in therapeutic-area focus (dermatology, oncology, respiratory) and emerging-market footprint.
• Lupin: Indian peer with parallel generics, API, and biosimilars businesses focused on the US, India, and emerging markets. Particularly comparable in complex generics and specialty therapy areas like oncology and respiratory.

Broad incumbents

• Sandoz (Novartis): Global generics and biosimilars leader spun out from Novartis. Direct overlap with Dr. Reddy's biosimilars franchise (Bevacizumab, Rituximab, etc.) and broad geographic reach across the US and Europe.
• Viatris (formerly Mylan): Global pharma major formed from the Mylan-Upjohn combination with deep generics, biosimilars, and branded specialty portfolios. Competes head-to-head with Dr. Reddy's in US generics and emerging markets.
• Teva Pharmaceutical Industries: Largest global generics player with deep US, EU, and emerging-market footprint plus specialty and biosimilars. A broader incumbent offering overlapping capabilities including complex generics and biosimilars that compete with Dr. Reddy's portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/drreddys
• YouTubeyoutube.com/drreddys
• Facebookfacebook.com/Dr.ReddysLaboratoriesLtd
• LinkedInlinkedin.com/company/dr--reddys-laboratories

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries4 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dr. Reddy’s Laboratories